Background: Interleukin 32 (IL-32) is a recently described pro-inflammatory cytokine implicated in chronic hepatitis C virus (HCV)-related inflammation and fibrosis. IL-32α is the most abundant IL-32 isoform. Methods: Circulating IL-32α levels were documented in patients with chronic HCV infections (n = 31) and compared with individuals who spontaneously resolved HCV infection (n = 14) and HCV-naive controls (n = 20). In addition, peripheral blood mononuclear cells (PBMC) from the chronic HCV (n = 12) and HCV-naive (n = 9) cohorts were investigated for responses to HCV core and non-structural (NS)3 protein induced IL-32α production. Finally, correlations between IL-32α levels, hepatic fibrosis and subsequent responses to interferon-based therapy were documented in patients with chronic HCV. Results: Circulating IL-32α levels in patients with chronic HCV were similar to those of spontaneously resolved and HCV-naive controls. HCV protein induced IL-32α responses were similar in chronic HCV patients and HCV-naive controls. In patients with chronic HCV, serum IL-32α levels correlated with worsening METAVIR fibrosis (F) scores from F0 to F3 (r = 0.596, P < 0.001) as did NS3 induced IL-32α responses (r = 0.837, P < 0.05). However, these correlations were not sustained with the inclusion of IL-32α levels at F4 scores, suggesting events at F4 interfere with IL-32α synthesis or release. In chronic HCV patients who underwent treatment (n = 28), baseline in vivo and in vitro induced IL-32α concentrations were not predictive of therapeutic outcomes. Conclusions: IL-32α activity is associated with worsening fibrosis scores in non-cirrhotic, chronic HCV patients.
Background: Interleukin 32 (IL-32) is a recently described pro-inflammatory cytokine implicated in chronic hepatitis C virus (HCV)-related inflammation and fibrosis. IL-32α is the most abundant IL-32 isoform. Methods: Circulating IL-32α levels were documented in patients with chronic HCV infections (n = 31) and compared with individuals who spontaneously resolved HCV infection (n = 14) and HCV-naive controls (n = 20). In addition, peripheral blood mononuclear cells (PBMC) from the chronic HCV (n = 12) and HCV-naive (n = 9) cohorts were investigated for responses to HCV core and non-structural (NS)3 protein induced IL-32α production. Finally, correlations between IL-32α levels, hepatic fibrosis and subsequent responses to interferon-based therapy were documented in patients with chronic HCV. Results: Circulating IL-32α levels in patients with chronic HCV were similar to those of spontaneously resolved and HCV-naive controls. HCV protein induced IL-32α responses were similar in chronic HCV patients and HCV-naive controls. In patients with chronic HCV, serum IL-32α levels correlated with worsening METAVIR fibrosis (F) scores from F0 to F3 (r = 0.596, P < 0.001) as did NS3 induced IL-32α responses (r = 0.837, P < 0.05). However, these correlations were not sustained with the inclusion of IL-32α levels at F4 scores, suggesting events at F4 interfere with IL-32α synthesis or release. In chronic HCV patients who underwent treatment (n = 28), baseline in vivo and in vitro induced IL-32α concentrations were not predictive of therapeutic outcomes. Conclusions: IL-32α activity is associated with worsening fibrosis scores in non-cirrhotic, chronic HCV patients.
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Alexander R Moschen; Teresa Fritz; Andrew D Clouston; Ilka Rebhan; Oliver Bauhofer; Helen D Barrie; Elizabeth E Powell; Soo-Hyun Kim; Charles A Dinarello; Ralf Bartenschlager; Julie R Jonsson; Herbert Tilg Journal: Hepatology Date: 2011-05-14 Impact factor: 17.425
Authors: P Felaco; M L Castellani; M A De Lutiis; M Felaco; F Pandolfi; V Salini; D De Amicis; J Vecchiet; S Tete; C Ciampoli; F Conti; G Cerulli; A Caraffa; P Antinolfi; C Cuccurullo; A Perrella; T C Theoharides; P Conti; E Toniato; D Kempuraj; Y B Shaik Journal: J Biol Regul Homeost Agents Date: 2009 Jul-Sep Impact factor: 1.711
Authors: Mihai G Netea; Tania Azam; Eli C Lewis; Leo A B Joosten; Maorong Wang; Dennis Langenberg; Xianzhong Meng; Edward D Chan; Do-Young Yoon; Tom Ottenhoff; Soo-Hyun Kim; Charles A Dinarello Journal: PLoS Med Date: 2006-08 Impact factor: 11.069